🇺🇸 FDA
Pipeline program

TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

M-14867-33

Phase 3 small_molecule active

Quick answer

TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment for Actinic Keratosis on the Face or Scalp is a Phase 3 program (small_molecule) at Almirall with 1 ClinicalTrials.gov record(s).

Program details

Company
Almirall
Indication
Actinic Keratosis on the Face or Scalp
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials